Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pralatrexate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR known ✓ | P00374 | 14/20 | 1.00 |
| ▸ | FOLR1 | P15328 | 2/20 | 1.00 |
| ▸ | SLC19A1 | P41440 | 2/20 | 1.00 |
| ▸ | SLC46A1 | Q96NT5 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | TLR4 | O00206 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | TYMS | P04818 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | GART | P22102 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pralatrexate SCHEMBL29904921 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL1889869 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL15075302 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL1890561 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL21633 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL2336143 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL29904925 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL17554355 | 0.99 | DHFR (0.98) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL17554353 | 0.99 | DHFR (0.98) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL28201941 | 0.99 | DHFR (0.98) | DHFRFOLR1SLC19A1SLC46A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2009 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| EP-3706801-B1 | PLATINUM COMPLEXES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-20250241923-A1 | A DUAL SELECTIVE PI3K DELTA AND GAMMA INHIBITORS AND/OR A SALT-INDUCIBLE KINASE 3 INHIBITOR FOR TREATING SOLID TUMORS | Incozen Therapeutics Pvt. Ltd (IN) | 2025-07-31 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-3710001-B1 | COMPOUNDS AND METHODS FOR REGULATING, LIMITING, OR INHIBITING AVIL EXPRESSION | UNIV VIRGINIA PATENT FOUNDATION (US) | 2025-06-18 | — | — | EP | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | claimed |
| EP-3426657-B1 | 2 AMINO N [7 METHOXY 2, 3-DIHYDROIMIDAZO-[1, 2-C]QUINAZOLIN-5-YL]PYRIMIDINE 5 CARBOXAMIDES | Bayer Pharma AG (DE) | 2022-07-13 | — | — | EP | claimed |
| EP-3278803-B1 | SOLID PHARMACEUTICAL DOSAGE FORM OF PARP INHIBITOR, AND APPLICATION OF SOLID PHARMACEUTICAL DOSAGE FORM OF PARP INHIBITOR | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2022-06-22 | — | — | EP | claimed |
| WO-2022109619-A1 | POLYMER VIALS HAVING STANDARD EXTERNAL DIMENSIONS AND REDUCED INTERNAL VOLUME | SIO2 MEDICAL PRODUCTS, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20220161969-A1 | PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS | OAKTREE FUND ADMINISTRATION, LLC | 2022-05-26 | — | — | US | claimed |
| EP-3288558-B1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma AG (DE) | 2022-05-11 | — | — | EP | claimed |
| US-11298293-B2 | PECVD coated pharmaceutical packaging | SIO2 MEDICAL PRODUCTS, INC. (US) | 2022-04-12 | — | — | US | claimed |
| WO-2022036024-A9 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| WO-2022036024-A2 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-02-17 | — | — | WO | claimed |
| WO-2022035723-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | THE BROAD INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | claimed |